Advanced search
Publication Cover
Drug Development and Industrial Pharmacy Volume 35, 2009 - Issue 1
Submit an article Journal homepage
165
Views
3
CrossRef citations to date
0
Altmetric
Research Article

Development and Evaluation of a pH-Dependent Sustained Release Tablet for Irritable Bowel Syndrome

Shuang-Qing ZhangCorrespondence[email protected]
,
Ziyaur Rahman Department of Pharmaceutics, School of Pharmacy, The University of Mississippi, University, MS, USA
,
Sridhar Thumma Department of Pharmaceutics, School of Pharmacy, The University of Mississippi, University, MS, USA
,
Michael A. Repka Department of Pharmaceutics, School of Pharmacy, The University of Mississippi, University, MS, USACorrespondence[email protected]
,
Guo-Hua Chen Institute of Vegetables and Flowers, Chinese Academy of Agricultural Sciences, Beijing, China
&
San-Ming Li Department of Physical Chemistry, Shenyang Pharmaceutical University, Shenyang, China
Pages 57-64 | Published online: 01 Jan 2009

REFERENCES

  • S. Appel, A. Kumle, M. Hubert, and T. Duvauchelle. (1997). First pharmacokinetic-pharmacodynamic study in humans with a selective 5-hydroxytryptamine4 receptor agonist. J. Clin. Pharmacol 37:229–237.
  • S. Appel-Dingemanse, Y. Hirschberg, S. Osborne, F. Pommier, and J. McLeod. (2001a). Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919). Eur. J. Clin. Pharmacol 56:889–891.
  • S. Appel-Dingemanse, A. Horowitz, J. Campestrini, S. Osborne, and J. McLeod. (2001b). The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects-male and female, elderly and young. Aliment. Pharmacol. Ther 15:937–944.
  • S. Appel-Dingemanse, M. O. Lemarechal, A. Kumle, M. Hubert, and E. Legangneux. (1999). Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration. Br. J. Clin. Pharmacol 47:483–491.
  • M. Ashford, and T. Fell. (1994). Targeting drugs to the colon: delivery systems for oral administration. J. Drug Target. 2:241–258.
  • M. E. Aulton, and A. M. Twitchell. (1995). Solution properties and atomization in film coating. InJ. E. Hogan, M. E. Aulton. (Eds.), Pharmaceutical coating technology ( pp. 64–117). London: Taylor & Francis.
  • P. Costa, and J. M. Sousa Lobo. (2001). Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 13:123–133.
  • J. T. Fell, and E. Efentakis. (1979). Contact angle determinations on pharmaceutical powders: A comparison of two methods. Int. J. Pharm. 4:153–157.
  • M. A. Frohoff-Hulsmann, A. Schmitz, and B. C. Lippold. (1999). Aqueous ethyl cellulose dispersions containing plasticizer of different water solubility and hydroxypropyl methyl cellulose as coating material for diffusion pellets: I. Drug release rates from coated pellets. Int. J. Pharm. 177:69–82.
  • M. Fox, D. Menne, B. Stutz, M. Fried, and W. Schwizer. (2006). The effects of tegaserod on oesophageal function and bolus transport in healthy volunteers: studies using concurrent high-resolution manometry and videofluoroscopy. Aliment. Pharmacol. Ther. 24:1017–1027.
  • J. Gutiérrez-Rocca, and J. W. McGinity. (1994). Influence of water soluble and insoluble plasticizer on the physical and mechanical properties of acrylic resin copolymers. Int. J. Pharm. 103:293–301.
  • S. K. Hadley, and S. M. Gaarder. (2005). Treatment of irritable bowel syndrome. Am. Fam. Phys. 72:2501–2506.
  • J. E. Hogan. (Ed.). (1995). Film-coating materials and their properties. Pharmaceutical coating technology ( pp. 6–52). London: Taylor & Francis.
  • A. P. Hungin, P. J. Whorwell, J. Tack, and F. Mearin. (2003). The prevalence, patterns and impact of irritable bowel syndrome: An international survey of 40,000 subjects. Aliment. Pharmacol. Ther. 17:643–650.
  • C. F. Lerk, A. J. Schoonen, and J. T. Fell. (1976). Contact angles and wetting of pharmaceutical powders. J. Pharm. Sci. 65:843–847.
  • I. N. Levine. (1995). Physical chemistry (4th ed.). New York: McGraw-Hill.
  • Organization for Economic Co-operation and Development. (2006). Guidelines for the testing of chemicals, partition coefficient (1-octanol/water): Slow-stirring method. http//www.sourceoecd.org/vl=12691240/cl=13/nw=1rpsv/cgibin/fulltextew.pl?prpsv=/ij/oecdjournals/1607310x/v1n1/s22/p1.idx.
  • A. Rivkin. (2003). Tegaserod maleate in the treatment of irritable bowel syndrome: A clinical review. Clin. Ther. 25:1952–1974.
  • V. P. Shah, Y. Tsong, P. Sathe, and J. P. Liu. (1998). In vitro dissolution profile comparison-statistics and analysis of the similarity factor, f2. Pharm. Res. 15:889–896.
  • S. K. Swan, H. Zhou, A. Horowitz, L. Alladina, M. Hubert, S. Appel-Dingemanse, S. Osborne, L. Lambrecht, and J. F. McLeod. (2003). Tegaserod pharmacokinetics are similar in patients with severe renal insufficiency and in healthy subjects. J. Clin. Pharmacol. 43:359–364.
  • N. J. Talley, M. Camilleri, D. Burton, G. Thomforde, K. Koch, M. J. Rucker, J. Peterson, A. R. Zinsmeister, and D. L. Earnest. (2006). Double-blind, randomized, placebo-controlled study to evaluate the effects of tegaserod on gastric motor, sensory and myoelectric function in healthy volunteers. Aliment. Pharmacol. Ther. 24:859–867.
  • U.S. Food and Drug Administration. (1997). Guidance for industry, extended release oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations. http://www.fda.gov/cder/guidance/1306fnl.pdf.
  • H. Zhou, S. Khalilieh, H. Lau, M. Guerret, S. Osborne, L. Alladina, A. L. Laurent, and J. F. McLeod. (1999). Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919). J. Clin. Pharmacol. 39:911–919.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.